دورية أكاديمية
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
| العنوان: | Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma. |
|---|---|
| المؤلفون: | Federico, Massimo, Fortpied, Catherine, Stepanishyna, Yana, Gotti, Manuel, van der Maazen, Richard, Cristinelli, Caterina, Re, Alessandro, Plattel, Wouter, Lazarovici, Julien, Merli, Francesco, Specht, Lena, Schiano de Colella, Jean-Marc, Hutchings, Martin, Versari, Annibale, Edeline, Véronique, Stamatoulas, Aspasia, Girinsky, Theodore, Ricardi, Umberto, Aleman, Berthe, Meulemans, Bart, Tonino, Sanne, Raemaekers, John, André, Marc |
| المساهمون: | UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie |
| المصدر: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, no. 1, p. 19-25 (2023) |
| سنة النشر: | 2023 |
| المجموعة: | DIAL@USL-B (Université Saint-Louis, Bruxelles) |
| الوصف: | JCO The primary analysis of the Early positron emission tomography (ePET) Response-Adapted Treatment in localized Hodgkin Lymphoma H10 Trial demonstrated that in ePET-negative patients, the risk of relapse increased when involved-node radiotherapy (INRT) was omitted and that in ePET-positive patients, switching from doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) significantly improved 5-year progression-free survival (PFS). Here, we report the final results of a preplanned analysis at a 10-year follow-up. In the favorable (F) ePET-negative group, the 10-year PFS rates were 98.8% versus 85.4% (hazard ratio [HR], 13.2; 95% CI, 3.1 to 55.8; value for noninferiority = .9735; difference test < .0001) in favor of ABVD + INRT; in the unfavorable (U) ePET-negative group, the 10-year PFS rates were 91.4% and 86.5% (HR, 1.52; 95% CI, 0.84 to 2.75; value for noninferiority = .8577; difference test = .1628). In ePET-positive patients, the difference in terms of PFS between standard ABVD and intensified BEACOPPesc was no longer statistically significant (HR, 0.67; 95% CI, 0.37 to 1.20; = .1777). In conclusion, the present long-term analysis confirms that in ePET-negative patients, the omission of INRT is associated with lower 10-year PFS. Instead, in ePET-positive patients, no significant difference between standard and experimental arms emerged although intensification with BEACOPPesc was safe, with no increase in late adverse events, namely, second malignancies. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1527-7755 |
| العلاقة: | boreal:281183; http://hdl.handle.net/2078.1/281183Test; info:pmid/37967311; urn:EISSN:1527-7755 |
| DOI: | 10.1200/JCO.23.01745 |
| الإتاحة: | https://doi.org/10.1200/JCO.23.01745Test http://hdl.handle.net/2078.1/281183Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.97E2F73F |
| قاعدة البيانات: | BASE |
| تدمد: | 15277755 |
|---|---|
| DOI: | 10.1200/JCO.23.01745 |